The Yin and Yang of clinical decision making before prescribing medical marijuana

Sharon Cirone
Ruth Dubin
Mel Kahan
Lori Montgomery
Conflict of interest statements:

• Sharon Cirone: none
• Ruth Dubin: none
• Mel Kahan: none
• Lori Montgomery: none
Learning objectives:
At the end of this workshop the participants will be able to

• Understand the potential impact of the new marijuana prescribing legislation.
• Conduct an assessment of the potential risks and harms of medical marijuana.
• Come to a patient-centered, evidence-based decision about safe marijuana prescribing.
Audience feedback: Show of hands

• How many of you have patients who have asked for or use cannabis?
• How many of you have concerns and worries about patients requesting medical cannabis?
• How many of you are comfortable prescribing medical cannabis?

http://www.cfpc.ca/cannabis_orientation_preliminaire/
• If considering authorizing dried cannabis for treatment of neuropathic pain, the physician should first consider a) adequate trials of other pharmacologic and non-pharmacologic therapies and b) an adequate trial of pharmaceutical cannabinoids (Level I).
Recommendation 4

Dried cannabis is not appropriate for patients who:

• a) Are under the age of 25 (Level II)
• b) Have a personal history or strong family history of psychosis (Level II)
• c) Have a current or past cannabis use disorder (Level III)
• d) Have an active substance use disorder (Level III)
• e) Have cardiovascular disease (angina, peripheral vascular disease, cerebrovascular disease, arrhythmias) (Level III)
• f) Have respiratory disease (Level III) or
• g) Are pregnant, planning to become pregnant, or breastfeeding (Level II)
Recommendation 5

Dried cannabis should be authorized with caution in those patients who:

• a) Have a concurrent active mood or anxiety disorder (Level II)
• b) Smoke tobacco (Level II)
• c) Have risk factors for cardiovascular disease (Level III) or
• d) Are heavy users of alcohol or taking high doses of opioids or benzodiazepines or other sedating medications prescribed or available over the counter (Level III)
Recommendation 7

Physicians should assess and monitor all patients on cannabis therapy for potential misuse or abuse (Level III).

• If the patient does not use substances problematically and begins cannabis treatment, the physician should ask the patient at each office visit about cognitive and mood-altering effects, as well as compliance with the dosing recommendations and use of any other substances. Periodic urine drug screens are advised.
Recommendation 9

The physician should regularly monitor the patient’s response to treatment with dried cannabis, considering the patient’s function and quality of life in addition to pain relief (Level III). The physician should discontinue authorization if the therapy is not clearly effective or is causing the patient harm (Level III).
Recommendation 10

• Patients taking dried cannabis should be advised not to drive for at least:
  • a) Four hours after inhalation (Level II)
  • b) Six hours after oral ingestion (Level II)
  • c) Eight hours after inhalation or oral ingestion if the patient experiences euphoria (Level II)
What’s an FP to do? Case # 1: Mr J.

- 45 year old man, prior history of left L5/S1 discectomy due to persistent pain/foot drop. Good results X 3 years then pain returned after minor injury at work
- Despite physiotherapy, referrals to orthopedics, injections – epidural steroids, IV lidocaine, pain worsened
- Mood: depressed – early childhood adversity, shunned by family (religious differences), benefits cut off by workmen’s compensation,
- Given venlafaxine by psychiatrist: severe suicidal ideation, ended up admitted overnight
- Not willing to try any more drugs!
Mr J’s pain drawing

Pain descriptors:

- Numbness
- Burning
- Pins and needles
- Aching
- Stabbing
- Like electric shocks
Mr J’s SENSORY EXAM

- Cotton balls
- Safety pin
- Brush
- Tuning fork
- Warm and cold water
Symptoms and physical exam:

- patient has allodynia, hyperalgsia around scar, in dermatome and generally over entire back
- Reduced range of motion, stiff gait, has to stand all the time as too painful to sit down
Began using marijuana on his own: significant pain relief, sleep better, mood up and down

• FP advised re safer use (Do not mix with tobacco, use vapourizer)

• Opioid Risk tool score: 4 (personal history of alcohol abuse, depression)

• Trial of nabilone: not covered, could not afford

• Trial of pregabalin: afraid to try

• Continued to use marijuana: used orally in butter/brownies

• Previously was on the MMAR (specialist supported use of mj)
Audience Feedback

• How many of you would agree with this patient’s treatment
• What might you have done instead?
• What worries you about this patient?
Six years Later:

- Still having good pain relief
- Sleep better
- **Function better**
- Eventually accepted for LTD, insurance claim accepted
- Enjoyed fishing, plans to open a bait shop
- Has now got a partner in his life
- No adverse effects (urine drug screens as normal)
- No escalation of dose, no aberrant behaviours etc
- Still drinking some beer, less than before
What was the most important factor in this patient’s symptomatic improvement?

• Use of medical marijuana?
• Acceptance for long-term disability and financial stability?
• Long-term relationship?
• Supportive relationship with an understanding primary care provider?
• Who cares? He now has some quality of life.
THE DARK SIDE OF MEDICAL CANNABIS:

• Tweet sent by http://medpotnow.com/cannabis-menu/

  “Potent indica dominant hybrid that may take you to a galaxy far, far away”

  (indica 70%, sativa 30%, 25% THC; $10 per gram)
ASK THE ADDICTION SPECIALIST

(SHARON CIRONE)

• DO YOU HAVE ANY CONCERNS WITH THE ABOVE PATIENT’S MANAGEMENT?
• WHAT IF HE WAS 18 YEARS OLD?
• WHAT ABOUT HIS HISTORY OF ALCOHOL MISUSE?
• WHAT IF HE BREAKS UP WITH HIS GIRLFRIEND AND STARTS DRINKING MORE ALCOHOL?
• WHAT ABOUT THE MEDICAL DIPSENSARY’s ADVERTISEMENTS?
Youth with Chronic Pain:

- Acute pain is common
- Chronic pain not a common presentation
- Adequate trials of non-pharmacotherapy interventions
- Trials of pharmacotherapy
- Pharmaceutical cannabinoids
- Avoid smoked cannabis: risk vs benefit
Teenage Brain Development and Vulnerability to Drug Use
Neurocognitive Effects of Cannabis Use

- Decreased IQ
- Neurocognitive damage
- Risk of addiction
The Link between Cannabis Use and Psychosis

- Increasing presentations of cannabis induced psychosis
- Exploring the link
- Increased access with new legislation?
Message for youth and parents

“Regular cannabis use is not safe”

“Delay the onset of cannabis use past the sensitive period of significant neuro-maturation”

“Parents lock up your medical marijuana- what may be safe for you is not safe for your children and teens”
Youth, Alcohol and Substance Use

- Student surveys of last year use: > 50% alcohol, up to 25% marijuana, < 10% daily use

- Poly-substance Use

- Deaths are associated with over-sedation and poor decision making
Youth, Alcohol and Substance Use

• Marijuana is associated with legal consequences

• Requests for prescribing for harm reduction
Youth, Emotional Distress and Chemical Coping

- Distress tolerance
- Undifferentiated mental health and psychiatric illnesses
- “Self medicating”
- “hand, pill and mouth disease”
- Healthy coping behaviors
- Resilience
Licensed Producers

LSD, Girl Guide Cookies

Nyce N’ Ez, Happy Face
Case # 2: Pain description: Mel Kahan

- 37 year old man requests medical marijuana
- Has four year history of severe back pain
- Localized to lower back, sometimes down legs
- Triggered by lifting a heavy object
- Pain is constant, 5-7/10
Pain description (2)

• Renders him unable to work, interferes with his sleep, makes him depressed
• Exam shows discomfort on lateral bending, nil else
• X-ray shows mild degenerative changes
Medications

• Hydromorph Contin 18 mg BID
  • Helps a little bit
• Clonazepam 0.5 mg tid
• Citalopram 20 mg OD
• Discontinued meds
  • NSAIDs - ineffective
  • Nabilone (cesamet) - ineffective
Psychosocial

• Is unable to work because of back pain and depression - on provincial disability plan
• Lives alone, not active
• Smokes 1 pack of cigarettes per day
• Drinks small amounts on occasion
• No other substance use
• Is depressed because of pain
  • No history of anxiety, psychosis, suicide ideation or attempts
His cannabis use history:

• Smokes 4-5 joints/day on average, 1 joint every 4-6 hours, two at night for sleep
• Not sure of size or potency of joint
• Assuming 500 mg/joint, then he’s smoking 2 – 2.5 grams/day, within the 1-3 grams/day promoted by the cannabis companies
• Doesn’t know potency
• Does admit to feeling anxious in the AM “Doc that’s why I need my clonazepam”
HE INSISTS THAT HE HAS TO USE CANNABIS
Questions

• Would you prescribe for him? Why or why not?
• What further information do you want?
Cannabis use disorder

• Signs of cannabis use disorder:
  • Smoking large amounts eg 2+ grams/day
  • Spending large amounts of time smoking
  • Poor social, work, school function
  • High value placed on cannabis (salience)
  • No clear medical indication
Management

• Don’t prescribe dried cannabis to this patient!
• Provide advice on tapering cannabis, opiates, and benzodiazepines
• Consider use of pharmaceutical cannabinoids to relieve withdrawal symptoms
• Counsel on harms of cannabis
  • Patients with CUD will likely experience improved pain, mood and function with abstinence
• Refer for addiction treatment
Medical marijuana and other drugs

• Patients who report using medical marijuana, when compared to other patients with similar pain conditions:
  • Are more likely to use opioids problematically
  • Are more likely to use cocaine
  • Have worse psychosocial function
Marijuana + other substance use: Management

Don’t prescribe for pain unless evidence available:

• I.e. Neuropathic pain not responding to other Rx

• Patient should agree to treatment for concurrent problem

• Taper prescribed opioids and benzodiazepines
Assessment

• In all patients requesting medical marijuana:
• Take a detailed history of current use of marijuana, alcohol, tobacco, opioids, cocaine and other drugs
• Ask about past use
• Ask if they have ever received treatment for problematic substance use
• Consider screening tools eg CAGE-AID
Ask the pain specialist? (Lori)

• What can you offer this patient in lieu of medical cannabis?
• How can a provider say “no” and still remain patient-centered
The “bottom line”

• Physicians are expected to know and comply with the regulations and policies of their College.

• Physicians are not obliged to complete a medical document for medical marijuana if they are unfamiliar with its treatment use or feel it is medically inappropriate.

http://www.cmpa-acpm.ca/cmpapd04/docs/resource_files/web_sheets/2013/com_w13_005-e.cfm
The “bottom line”

• If a physician chooses to complete a medical document, it is important that a meaningful consent discussion be held, and that the consent discussion be captured in the medical record.

• Members should not hesitate to contact the CMPA for advice on this issue.
Neuropathic pain
Fibromyalgia
Back pain
HIV neuropathy
MS pain
Muscle spasm
Myofascial pain
Pelvic pain
Migraine
Tension headache

Patients will swear on the bible that it helps!
Evidence: case reports, N < 10, no placebo
Better evidence for opiates........where are we now?
Clearly proven risks and benefits for pain patients:

Cannabinoids

Location of CB receptors

brain
brainstem
spinal cord

primary afferent receptor
Evidence to date
(all neuropathic pain)


Evidence to date

• Average N=30
• Duration of studies ≤5 days
• All previous smokers of marijuana
• Amounts ranging 25mg-900mg
• Smoking or vapourizing
• THC ≤9.4%
  • One study 20% not an efficacy study, n=8
• Reduction in pain ranging from 0.7 to 3 points on the NRS
A logical approach in this patient

• Evidence is in its early stages, and this isn’t a therapy for everyone
• The evidence we have suggests that if cannabis is going to be helpful, it is in very low doses compared to what this patient is using
• Benefits may be in reducing pain related distress
• There are many other ways of reducing this distress
• Evidence is evolving on a virtually daily basis, and it’s logical to return to this discussion regularly
Audience Questions and feedback